Last10K.com

Amphastar Pharmaceuticals, Inc. (AMPH) SEC Filing 10-K Annual report for the fiscal year ending Tuesday, December 31, 2019

Amphastar Pharmaceuticals, Inc.

CIK: 1297184 Ticker: AMPH

EXHIBIT 99.1

 

Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2019

 

Reports Net Revenues of $83.4 Million for the Three Months Ended December 31, 2019

 

RANCHO CUCAMONGA, CA –  March 12, 2020  – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months and full year ended December 31, 2019.

 

Fourth Quarter Highlights

 

·

Net revenues of $83.4 million for the fourth quarter

·

GAAP net loss of $1.0 million, or $(0.02) per share, for the fourth quarter

·

Adjusted non-GAAP net income of $3.6 million, or $0.07 per share, for the fourth quarter

 

Full Year Highlights

 

·

Net revenues of $322.4 million for the fiscal year

·

GAAP net income of $48.9 million, or $0.98 per share, for the fiscal year

·

Adjusted non-GAAP net income of $17.8 million, or $0.36 per share, for the fiscal year

 

Dr. Jack Zhang, Amphastar’s Chief Executive Officer, commented: “We finished 2019 with very strong sales of Primatene® Mist, with fourth quarter sales essentially equaling sales in the previous three quarters combined. Additionally, we have made great progress with our pipeline of product candidates,  as we continue to move forward with clinical trials for both our insulin and inhalation products. In addition, the FDA accepted two more of our ANDAs.”

   

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Year Ended

 

 

 

December 31, 

 

December 31, 

 

 

 

2019

 

2018

 

2019

 

2018

 

 

 

(in thousands, except per share data)

 

Net revenues

    

$

83,383

    

$

89,690

    

$

322,357

    

$

294,666

 

GAAP net income (loss) attributable to Amphastar

 

$

(1,026)

 

$

1,867

 

$

48,939

 

$

(5,738)

 

Adjusted non-GAAP net income attributable to Amphastar*

 

$

3,639

 

$

6,231

 

$

17,810

 

$

10,399

 

GAAP diluted EPS attributable to Amphastar shareholders

 

$

(0.02)

 

$

0.04

 

$

0.98

 

$

(0.12)

 

Adjusted non-GAAP diluted EPS attributable to Amphastar shareholders*

 

$

0.07

 

$

0.13

 

$

0.36

 

$

0.21

 


The following information was filed by Amphastar Pharmaceuticals, Inc. (AMPH) on Thursday, March 12, 2020 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Amphastar Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Amphastar Pharmaceuticals, Inc..

Continue

Assess how Amphastar Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Amphastar Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Revenue
Financial
M & A
Other
Filter Subcategory:
All
Product
Expense
Shares
Geography
Earnings
Cash Flow
Debt
Other
Inside Amphastar Pharmaceuticals, Inc.'s 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (Parenthetical)
Condensed Consolidated Statements Of Cash Flows
Condensed Consolidated Statements Of Comprehensive Income (Loss)
Condensed Consolidated Statements Of Operations
Consolidated Statements Of Stockholders??? Equity
Accounts Payable And Accrued Liabilities
Accounts Payable And Accrued Liabilities (Details)
Accounts Payable And Accrued Liabilities (Tables)
Business
Business Acquisitions
Business Acquisitions (Details)
Commitments And Contingencies
Commitments And Contingencies (Future Minimum Rental Payments) (Details)
Commitments And Contingencies (Lease Cash Flow Information) (Details)
Commitments And Contingencies (Lease Expense) (Details)
Commitments And Contingencies (Purchase Commitments) (Details)
Commitments And Contingencies (Tables)
Customer And Supplier Concentration
Customer And Supplier Concentration (Details)
Customer And Supplier Concentration (Tables)
Debt
Debt (Long-Term Debt Maturities) (Details)
Debt (Narrative) (Details)
Debt (Schedule Of Debt) (Details)
Debt (Tables)
Employee Benefits
Employee Benefits (Details)
Fair Value Measurements
Fair Value Measurements (Fair Values Of The Company's Financial Assets And Liabilities) (Details)
Fair Value Measurements (Tables)
Goodwill And Intangible Assets
Goodwill And Intangible Assets (Summary Of Changes In The Carrying Amount Of Goodwill) (Details)
Goodwill And Intangible Assets (Summary Of Expected Amortization Expense) (Details)
Goodwill And Intangible Assets (Summary Of Intangible Assets) (Details)
Goodwill And Intangible Assets (Tables)
Income (Loss) Per Share Attributable To Amphastar Pharmaceuticals, Inc. Shareholders
Income (Loss) Per Share Attributable To Amphastar Pharmaceuticals, Inc. Shareholders (Calculation Of Basic And Diluted Net Income (Loss) Per Share) (Details)
Income (Loss) Per Share Attributable To Amphastar Pharmaceuticals, Inc. Shareholders (Narrative) (Details)
Income (Loss) Per Share Attributable To Amphastar Pharmaceuticals, Inc. Shareholders (Tables)
Income Taxes
Income Taxes (Narrative) (Details)
Income Taxes (Reconciliation Of The Statutory Federal Income Tax Rate To The Effective Tax Rate) (Details)
Income Taxes (Reconciliation Of Unrecognized Tax Benefits) (Details)
Income Taxes (Schedule Of Deferred Tax Assets/Liabilities) (Details)
Income Taxes (Summary Of Income Before Taxes) (Details)
Income Taxes (Summary Of Provision (Benefit) For Income Taxes) (Details)
Income Taxes (Tables)
Income Taxes (Uncertain Income Tax Positions - Narrative) (Details)
Inventories
Inventories (Details)
Inventories (Tables)
Investments
Investments (Held-To_Maturity) (Details)
Investments (Tables)
Litigation
Litigation (Details)
Property, Plant, And Equipment
Property, Plant, And Equipment (Narrative) (Details)
Property, Plant, And Equipment (Summary Of Property, Plant, And Equipment) (Details)
Property, Plant, And Equipment (Tables)
Quarterly Financial Data (Unaudited)
Quarterly Financial Data (Unaudited) (Details)
Quarterly Financial Data (Unaudited) (Tables)
Related-Party Transactions
Related-Party Transactions (Details)
Revenue Recognition
Revenue Recognition (Analysis Of Product Return Liability) (Details)
Revenue Recognition (Analysis Of The Chargeback Provision) (Details)
Revenue Recognition (Tables)
Segment Reporting
Segment Reporting (Depreciation And Amortization Expense By Reporting Segment) (Details)
Segment Reporting (Selected Financial Information By Reporting Segment) (Details)
Segment Reporting (Summary Of Net Revenues By Product Segment) (Details)
Segment Reporting (Summary Of Revenues And Long-Lived Assets By Geographic Region) (Details)
Segment Reporting (Tables)
Stockholders' Equity
Stockholders' Equity (2014 Employee Stock Purchase Plan) (Details)
Stockholders' Equity (Common And Preferred Stock) (Details)
Stockholders' Equity (Information Relating To Option Grants And Exercises) (Details)
Stockholders' Equity (Information Relating To Rsu Grants And Deliveries) (Details)
Stockholders' Equity (Key Assumptions Used In Determining Fair Value Of Options Granted) (Details)
Stockholders' Equity (Restricted Stock Units) (Details)
Stockholders' Equity (Share Buyback Program) (Details)
Stockholders' Equity (Share-Based Compensation Expense Included In The Statement Of Operations) (Details)
Stockholders' Equity (Summary Of Nonvested Options) (Details)
Stockholders' Equity (Summary Of Option Activity) (Details)
Stockholders' Equity (Tables)
Stockholders' Equity (The 2015 Equity Incentive Plan) (Details)
Stockholders' Equity (The 2018 Anp Equity Incentive Plan) (Details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Details)
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Recent Accounting Pronouncements) (Details)
Summary Of Significant Accounting Policies (Schedule Of Intangible Useful Lives) (Details)
Summary Of Significant Accounting Policies (Schedule Of Pp&Amp;E Useful Lives) (Details)
Summary Of Significant Accounting Policies (Tables)
Ticker: AMPH
CIK: 1297184
Form Type: 10-K Annual Report
Accession Number: 0001297184-20-000007
Submitted to the SEC: Mon Mar 16 2020 4:49:07 PM EST
Accepted by the SEC: Mon Mar 16 2020
Period: Tuesday, December 31, 2019
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/amph/0001297184-20-000007.htm